Photobiomodulation treatment vs no treatment/sham
Adverse events: AMD progression at 12 months Defined as increased drusen volume or onset of advanced AMD. Conversion to exudative AMD at 12 months Assessed by clinical examination and retinal optical coherence tomography. · people with non‐exudative AMD (AREDS 2 to 4)
Photobiomodulation treatment showed no clear difference in adverse events: AMD progression at 12 months Defined as increased… compared with sham or no treatment (low certainty).
1 finding from 1 review
- Photobiomodulation for non‐exudative age‐related macular degeneration 2021 · Cochrane Headline outcomes onlyRR 0.79 [0.41, 1.53]Studies not reportedLow